Drugs / INCB054329
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02431260 | Apr 2015 → Jan 2018 | hematopoietic and lymphoid system neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03896815 | — | — | Incyte Corporation | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-04-17 | Incyte Corporation | Results Incyte’s Emerging Development Pipeline Described in Eleven Abstracts at 2015 AACR Annual Meeting incyte.com ↗
Activity of the BET inhibitor INCB054329 in models of multiple myeloma. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-04-17 | Incyte Corporation | Incyte’s Emerging Development Pipeline Described in Eleven Abstracts at 2015 AACR Annual Meeting incyte.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB054329 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02431260 ↗ |
| Route | Oral | “Patients (≥18 years) with advanced malignancies, ≥1 prior therapy, and adequate organ functions received oral INCB054329 (monotherapy)” PMID 31527168 ↗ Sep 2019 |